KL
SRPT icon

Kam Lawrence’s Sarepta Therapeutics SRPT Stock Holding History

Kam Lawrence’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$14.5M Buy
+112,689
New +$11.4M 14.93% 3

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Kam Lawrence's SRPT Position: Q4 2019 in Review

Kam Lawrence opened a new position in Sarepta Therapeutics (SRPT) in Q4 2019: 112,689 shares worth $14.5M. The stake represents 14.93% of the portfolio and ranks #3 among its holdings.

389 funds tracked by Wall St. Rank hold SRPT as of Q4 2019.

  • Kam Lawrence held 112,689 shares of Sarepta Therapeutics worth $14.5M as of Q4 2019.
  • Sarepta Therapeutics was a new Kam Lawrence position in Q4 2019.
  • Sarepta Therapeutics made up 14.93% of Kam Lawrence's portfolio in Q4 2019, its #3 holding.
  • 389 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2019.

Based on Kam Lawrence's 13F filing for Q4 2019, filed 13 Feb 2020.